Compile Data Set for Download or QSAR
Report error Found 76 Enz. Inhib. hit(s) with all data for entry = 1155
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311101(US10155750, Example 38 | 2-(2,2- difluorocycloprop...)
Affinity DataIC50: 10nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311093(US10155750, Example 30 | N-ethyl-4-fluoro-N-(2- (4...)
Affinity DataIC50: 10nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311100(US10155750, Example 37 | 2-(2,2-difluoroethyl)- N-...)
Affinity DataIC50: 10nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311083(US10155750, Example 20)
Affinity DataIC50: 12nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311091(US10155750, Example 28 | 2-cyclopropyl-N- ethyl-N-...)
Affinity DataIC50: 13nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311103(US10155750, Example 40 | 2-cyclobutyl-N-ethyl- N-(...)
Affinity DataIC50: 13nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311110(US10155750, Example 48 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 13nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311102(US10155750, Example 39 | 2-cyclopropyl-N- ethyl-N-...)
Affinity DataIC50: 14nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311104(US10155750, Example 41 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 15nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311089(US10155750, Example 26 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 19nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311084(US10155750, Example 21)
Affinity DataIC50: 21nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311112(US10155750, Example 50)
Affinity DataIC50: 23nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311090(US10155750, Example 27 | 2-ethoxy-N-ethyl-N- (2-(4...)
Affinity DataIC50: 27nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311092(US10155750, Example 29 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 28nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311105(US10155750, Example 42 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 29nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311095(US10155750, Example 32 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 32nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311094(US10155750, Example 31 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 33nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311080(US10155750, Example 11 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 34nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311111(US10155750, Example 49)
Affinity DataIC50: 35nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311098(US10155750, Example 35 | 2-(2,2- difluoroethoxy)-N...)
Affinity DataIC50: 35nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311088(US10155750, Example 25 | 2-(difluoromethoxy)- N-et...)
Affinity DataIC50: 35nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311097(US10155750, Example 34 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 37nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311079(US10155750, Example 5 | N-ethyl-N-(2-(4-(2- hydrox...)
Affinity DataIC50: 41nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311087(US10155750, Example 24 | 2-(2,2- difluoroethoxy)-N...)
Affinity DataIC50: 44nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311078(US10155750, Example 4)
Affinity DataIC50: 47nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311096(US10155750, Example 33 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 52nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311075(US10155750, Example 1)
Affinity DataIC50: 58nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311086(US10155750, Example 23 | 2-ethoxy-N-ethyl-N- (2-(4...)
Affinity DataIC50: 58nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311085(US10155750, Example 22 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 61nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311076(US10155750, Example 2)
Affinity DataIC50: 65nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311108(US10155750, Example 45 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 87nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311107(US10155750, Example 44 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 106nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311082(US10155750, Example 18 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 145nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311106(US10155750, Example 43 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 180nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311109(US10155750, Example 47 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 239nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311081(US10155750, Example 12 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 247nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311099(US10155750, Example 36 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 270nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311077(US10155750, Example 3)
Affinity DataIC50: 373nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311103(US10155750, Example 40 | 2-cyclobutyl-N-ethyl- N-(...)
Affinity DataIC50: 1.17E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311101(US10155750, Example 38 | 2-(2,2- difluorocycloprop...)
Affinity DataIC50: 1.48E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311091(US10155750, Example 28 | 2-cyclopropyl-N- ethyl-N-...)
Affinity DataIC50: 1.56E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311104(US10155750, Example 41 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 2.10E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311095(US10155750, Example 32 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 2.21E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311102(US10155750, Example 39 | 2-cyclopropyl-N- ethyl-N-...)
Affinity DataIC50: 2.84E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311083(US10155750, Example 20)
Affinity DataIC50: 2.86E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311093(US10155750, Example 30 | N-ethyl-4-fluoro-N-(2- (4...)
Affinity DataIC50: 5.54E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311110(US10155750, Example 48 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 7.52E+3nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311105(US10155750, Example 42 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311106(US10155750, Example 43 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM311107(US10155750, Example 44 | N-ethyl-N-(2-(4-(2- hydro...)
Affinity DataIC50: 1.00E+4nMAssay Description:The cells are seeded at 20,000 cells/well into Becton-Dickinson black 384-well clear bottom sterile plates coated with poly-D-lysine. All reagents we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 76 total ) | Next | Last >>
Jump to: